European investment in research and development lags the United States, and European researchers relocate to the United States to take advantage of public research funding and more risk-tolerant capital markets. European public health systems provide more cost-effective access to pharmaceuticals than the U.S. system, by controlling prices and by assessing the comparative efficacy of new and older treatments. Europe provides substantially less funding for developing country procurement of HIV-AIDS treatment.
- Can European research and development be stimulated without sacrificing price controls? What inhibits a USNIH-style approach to public financing of R&D?
- Is the European Commission’s increasing focus on a “strong patent”-gap with the United States the right direction for increasing innovation?
- Will Russia emerge as a medicines innovator? How will its pharmaceutical industry integrate with the rest of the world? What improvements are needed in Russian regulatory governance?
- Does the coordination between European medicines regulatory authorities provide a potential model for other regions?
- Why does Europe lag the United States in financing HIV-AIDS treatment for populations in developing countries?